A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
The study will be conducted in about 51 participants in total. The purpose of this study is
to evaluate the safety, tolerability, pharmacokinetic profile and preliminary antitumor
efficacy of Hemay181 in patients with advanced solid tumors.